AR114354A2 - PYRIMIDINE DERIVATIVES - Google Patents
PYRIMIDINE DERIVATIVESInfo
- Publication number
- AR114354A2 AR114354A2 ARP190100267A ARP190100267A AR114354A2 AR 114354 A2 AR114354 A2 AR 114354A2 AR P190100267 A ARP190100267 A AR P190100267A AR P190100267 A ARP190100267 A AR P190100267A AR 114354 A2 AR114354 A2 AR 114354A2
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- unsubstituted
- alkoxy
- alkyl
- aryl
- Prior art date
Links
Abstract
Reivindicación 1: Un compuesto de fórmula (1), en donde cada uno de R⁰, R¹, R² y R³ es independientemente hidrógeno, alquilo C₁₋₈, alquenilo C₂₋₈, alquinilo C₂₋₈, cicloalquilo C₃₋₈, cicloalquilo C₃₋₈-alquilo C₁₋₈, aril C₅₋₁₀-alquilo C₁₋₈, hidroxialquilo C₁₋₈, alcoxi C₁₋₈-alquilo C₁₋₈, aminoalquilo C₁₋₈, haloalquilo C₁₋₈, arilo C₅₋₁₀ no sustituido o sustituido, heterociclilo de 5 ó 6 miembros no sustituido o sustituido que comprende 1, 2 ó 3 heteroátomos seleccionados de N, O y S, hidroxi, alcoxi C₁₋₈, hidroxialcoxi C₁₋₈, alcoxi C₁₋₈-alcoxi C₁₋₈, haloalcoxi C₁₋₈, aril C₅₋₁₀-alcoxi C₁₋₈ no sustituido o sustituido, heterocicliloxi no sustituido o sustituido, o heterociclilalcoxi C₁₋₈ no sustituido o sustituido, amino no sustituido o sustituido, alquiltio C₁₋₈, alquilsulfinilo C₁₋₈, alquilsulfonilo C₁₋₈, arilsulfonilo C₅₋₁₀, halógeno, carboxi, alcoxicarbonilo C₁₋₈, carbamoílo no sustituido o sustituido, sulfamoílo no sustituido o sustituido, ciano o nitro; o R⁰ y R¹, R¹ y R², y/o R² y R³ forman, junto con los átomos de carbono a los cuales están unidos, un anillo carbocíclico o heterocíclico de 5 ó 6 miembros que comprende 0, 1, 2 ó 3 heteroátomos seleccionados de N, O y S; R⁴ es hidrógeno o alquilo C₁₋₈; cada uno de R⁵ y R⁶ independientemente es hidrógeno, alquilo C₁₋₈, alcoxi C₁₋₈-alquilo C₁₋₈, haloalquilo C₁₋₈, alcoxi C₁₋₈, halógeno, carboxi, alcoxicarbonilo C₁₋₈, carbamoílo no sustituido o sustituido, ciano, o nitro; y cada uno de R⁷, R⁸, R⁹ y R¹⁰ independientemente es alquilo C₁₋₈, alquenilo C₂₋₈, alquinilo C₂₋₈, cicloalquilo C₃₋₈, cicloalquilo C₃₋₈-alquilo C₁₋₈, arilo C₅₋₁₀-alquilo C₁₋₈, hidroxialquilo C₁₋₈, alcoxi C₁₋₈-alquilo C₁₋₈, aminoalquilo C₁₋₈, haloalquilo C₁₋₈, arilo C₅₋₁₀ no sustituido o sustituido, heterociclilo de 5 ó 6 miembros no sustituido o sustituido que comprende 1, 2 ó 3 heteroátomos seleccionados de N, O y S, hidroxi, alcoxi C₁₋₈, hidroxialcoxi C₁₋₈, alcoxi C₁₋₈-alcoxi C₁₋₈, haloalcoxi C₁₋₈, arilo C₅₋₁₀-alcoxi C₁₋₈ no sustituido o sustituido, heterocicliloxi no sustituido o sustituido, o heterociclilalcoxi C₁₋₈ no sustituido o sustituido, amino no sustituido o sustituido, alquiltio C₁₋₈, alquilsulfinilo C₁₋₈, alquilsulfonilo C₁₋₈, arilsulfonilo C₅₋₁₀, halógeno, carboxi, alcoxicarbonilo C₁₋₈, carbamoílo no sustituido o sustituido, sulfamoílo no sustituido o sustituido, ciano o nitro; en donde R⁷, R⁸ y R⁹ independientemente entre sí también pueden ser hidrógeno; o R⁷ y R⁸, R⁸ y R⁹, y/o R⁹ y R¹⁰ forman junto con los átomos de carbono a los cuales están unidos, un anillo carbocíclico o heterocíclico de 5 ó 6 miembros que comprende 0, 1, 2 ó 3 heteroátomos seleccionados de N, O y S; A es C o N; y sus sales.Claim 1: A compound of formula (1), wherein each of R⁰, R¹, R² and R³ is independently hydrogen, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₃₋₈ cycloalkyl, C₃₋ cycloalkyl ₈-C₁₋₈ alkyl, C₅₋₁₀ aryl-C₁₋₈ alkyl, C₁₋₈ hydroxyalkyl, C₁₋₈ alkoxy-C₁₋₈ alkyl, C₁₋₈ aminoalkyl, C₁₋₈ haloalkyl, unsubstituted or substituted C₅₋₁₀ aryl , unsubstituted or substituted 5- or 6-membered heterocyclyl comprising 1, 2, or 3 heteroatoms selected from N, O and S, hydroxy, C₁₋₈ alkoxy, C₁₋₈ hydroxyalkoxy, C alco alkoxy-C₁₋₈ alkoxy, haloalkoxy C₁₋₈, unsubstituted or substituted C₅₋₁₀ aryl-C₁₋₈ alkoxy, unsubstituted or substituted heterocyclyloxy, or unsubstituted or substituted C₁₋₈ heterocyclylalkoxy, unsubstituted or substituted amino, C₁₋₈ alkylthio, C₁₋₈ alkylsulfinyl, C₁₋₈ alkylsulfonyl, C₅₋₁₀ arylsulfonyl, halogen, carboxy, C₁₋₈ alkoxycarbonyl, unsubstituted or substituted carbamoyl, unsubstituted or substituted sulfamoyl, cyano or nitro; or R⁰ and R¹, R¹ and R², and / or R² and R³ form, together with the carbon atoms to which they are attached, a 5- or 6-membered carbocyclic or heterocyclic ring comprising 0, 1, 2, or 3 selected heteroatoms of N, O and S; R⁴ is hydrogen or C₁₋₈ alkyl; each of R⁵ and R⁶ independently is hydrogen, C alqu alkyl, C₁₋₈ alkoxy-C₁₋₈ alkyl, C₁₋₈ haloalkyl, C₁₋₈ alkoxy, halogen, carboxy, C₁₋₈ alkoxycarbonyl, unsubstituted or substituted carbamoyl, cyano, or nitro; and each of R⁷, R⁸, R⁹ and R cada independently is C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₃₋₈ cycloalkyl, C₃₋₈ cycloalkyl-C alqu alkyl, C₅₋₁₀ aryl-C alqu alkyl ₋₈, C₁₋₈ hydroxyalkyl, C₁₋₈ alkoxy-C₁₋₈ alkyl, C₁₋₈ aminoalkyl, C₁₋₈ haloalkyl, unsubstituted or substituted C₅₋₁₀ aryl, unsubstituted or substituted 5- or 6-membered heterocyclyl comprising 1 , 2 or 3 heteroatoms selected from N, O and S, hydroxy, C₁₋₈ alkoxy, C₁₋₈ hydroxyalkoxy, C₁₋₈ alkoxy-C₁₋₈ alkoxy, C₁₋₈ haloalkoxy, C₅₋₁₀ aryl-C₁₋₈ alkoxy no substituted or substituted, unsubstituted or substituted heterocyclyloxy, or unsubstituted or substituted C₁₋₈ heterocyclylalkoxy, unsubstituted or substituted amino, C₁₋₈ alkylthio, C₁₋₈ alkylsulfinyl, C₁₋₈ alkylsulfonyl, C₅₋₁₀ arylsulfonyl, halogen, carboxy, C₁₋₈ alkoxycarbonyl, unsubstituted or substituted carbamoyl, unsubstituted or substituted sulfamoyl, cyano or nitro; where R⁷, R⁸ and R⁹ independently of each other can also be hydrogen; or R⁷ and R⁸, R⁸ and R⁹, and / or R⁹ and R¹⁰ form, together with the carbon atoms to which they are attached, a 5- or 6-membered carbocyclic or heterocyclic ring comprising 0, 1, 2, or 3 heteroatoms selected from N, O and S; A is C or N; and its salts.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0319227A GB0319227D0 (en) | 2003-08-15 | 2003-08-15 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
AR114354A2 true AR114354A2 (en) | 2020-08-26 |
Family
ID=28052593
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170100728A AR107965A2 (en) | 2003-08-15 | 2017-03-23 | PIRIMIDINE DERIVATIVES |
ARP190100267A AR114354A2 (en) | 2003-08-15 | 2019-02-04 | PYRIMIDINE DERIVATIVES |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170100728A AR107965A2 (en) | 2003-08-15 | 2017-03-23 | PIRIMIDINE DERIVATIVES |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN1832929B (en) |
AR (2) | AR107965A2 (en) |
GB (1) | GB0319227D0 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2671744C (en) * | 2006-12-08 | 2012-08-28 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
EP2432900A4 (en) * | 2009-05-15 | 2012-11-21 | Insight Genetics Inc | Methods and compositions relating to fusions of alk for diagnosing and treating cancer |
AU2013344049B2 (en) * | 2012-11-06 | 2017-12-21 | Fochon Pharmaceuticals, Ltd. | ALK kinase inhibitors |
EP2970205B1 (en) * | 2013-03-14 | 2019-05-08 | Tolero Pharmaceuticals, Inc. | Jak2 and alk2 inhibitors and methods for their use |
CN104628657A (en) * | 2013-11-06 | 2015-05-20 | 韩冰 | Class of compounds for treating ischemic brain damage and purpose thereof |
CN104926794B (en) * | 2014-03-17 | 2017-12-05 | 广东东阳光药业有限公司 | Substituted heteroaryl compound and combinations thereof and purposes |
CN106008503B (en) * | 2015-03-31 | 2020-09-01 | 齐鲁制药有限公司 | Spirocyclic aryl sulfones as protein kinase inhibitors |
CN106146525B (en) * | 2015-04-10 | 2018-11-02 | 山东轩竹医药科技有限公司 | Three and ring class anaplastic lymphoma kinase inhibitor |
CN106187915A (en) * | 2015-05-27 | 2016-12-07 | 上海翰森生物医药科技有限公司 | There is inhibitor of ALK Yu EGFR double activity and its preparation method and application |
CN106349224A (en) * | 2016-08-03 | 2017-01-25 | 山东大学 | JAK kinase inhibitor with 4-amino-(1H)-pyrazole structure and preparation method and application thereof |
CN110092759A (en) * | 2018-01-31 | 2019-08-06 | 陆柯潮 | The chloro- 2,4- pyrimidine derivatives of 5- as anti-tumor drug |
CN114716385B (en) * | 2022-04-08 | 2024-03-12 | 北京师范大学 | Compound of targeted focal adhesion kinase, preparation method and application |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0206215D0 (en) * | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
-
2003
- 2003-08-15 GB GB0319227A patent/GB0319227D0/en not_active Ceased
-
2004
- 2004-08-13 CN CN2004800227255A patent/CN1832929B/en active Active
-
2017
- 2017-03-23 AR ARP170100728A patent/AR107965A2/en unknown
-
2019
- 2019-02-04 AR ARP190100267A patent/AR114354A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
GB0319227D0 (en) | 2003-09-17 |
CN1832929B (en) | 2012-11-07 |
CN1832929A (en) | 2006-09-13 |
AR107965A2 (en) | 2018-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR114354A2 (en) | PYRIMIDINE DERIVATIVES | |
AR045458A1 (en) | PIRIMIDINE DERIVATIVES | |
AR107966A2 (en) | INHIBITING PYRIMIDINE AND PYRIDINE DERIVATIVES OF THE QUINASA PROTEIN | |
AR111279A1 (en) | USEFUL HETEROCYCLIC DERIVATIVES AS DUAL INHIBITORS OF ATX / CA | |
CO6251260A2 (en) | BIFENYLL DERIVATIVES CONFORMALLY RESTRICTED FOR USE AS INHIBITORS OF THE HEPATITIS VIRUS C. | |
CO5700764A2 (en) | DIHYDROQUINAZOLINS REPLACED WITH ANTIVIRAL PROPERTIES | |
CO6270328A2 (en) | PIRROLO DERIVATIVES [2,3] PYRIMIDINE AS INHIBITORS OF KINASE PROTEINS B | |
AR060651A1 (en) | DERIVATIVES OF 1,2,4-TRIAZOL AS MODULATORS OF MGLUR5 I, INTERMEDIARIES FOR SYNTHESIS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF PAIN AND GASTROINTESTINAL DISORDERS | |
CO5640117A2 (en) | 2,4-DIAMONOPIRIMIDINE DERIVATIVES | |
AR070463A1 (en) | AMINA AND ETER COMPOUNDS THAT MODULATE THE CB2 RECEIVER | |
CO4950625A1 (en) | NICOTINAMIDE DERIVATIVES | |
AR046083A1 (en) | DERIVATIVES OF 2 PIRIDONA AS INHIBITORS OF THE ELASTASA DE NEUTROFILOS | |
AR116913A1 (en) | APOL1 INHIBITORS AND THEIR USE METHODS | |
BRPI0519288A2 (en) | heterocyclic compounds as ccr2b antagonists | |
ES2271615T3 (en) | N-ARIL-2-OXAZOLIDINONA-5-CARBOXAMIDS AND ITS DERIVATIVES AND ITS USE AS ANTIBACTERIALS. | |
AR099498A1 (en) | TRIAZINE COMPOUNDS AND THEIR PHARMACEUTICAL USE | |
CO5690551A2 (en) | TETRAZOL DERIVATIVES AND METHODS FOR TREATMENT WITH THE SAME DISORDERS RELATED TO METABOLISM | |
AR096846A1 (en) | DIHYDROCHINOXALINONES AND MODIFIED DIHYDROPIRIDOPIRAZINONES AS INHIBITORS OF BET PROTEIN | |
AR060812A1 (en) | MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MGLUR5, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES IN PATOPHYSIOLOGICAL PROCESSES AND DISORDERS AFFECTING THE SCN | |
AR051325A1 (en) | BIARILQUINOLIN-4-ILAMINA SUBSTITUTED ANALOGS | |
AR110282A1 (en) | BICYCLIC AMIDA COMPOUNDS AND USE OF THESE IN THE TREATMENT OF DISEASES MEDIATED BY RIP1 | |
CO5720994A2 (en) | PIRROL REPLACED DERIVATIVES | |
AR060810A1 (en) | MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MGLUR5, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES IN PATOPHYSIOLOGICAL PROCESSES AND DISORDERS AFFECTING THE SCN | |
AR110498A1 (en) | DERIVATIVES OF ISOXAZOLIL Ether AS POSITIVE ALOSTERIC MODULATORS (PAM) OF GABAA RECEPTORS a5 | |
AR066604A1 (en) | DERIVATIVES OF ARILAMIDA PIRIMIDONA, MEDICINES THAT CONTAIN THEM AND THERAPEUTIC USES TO PREVENT AND / OR TREAT FUNDAMENTALALLY NEURODEGENERATIVE DISEASES. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |